Israel Englander Medicenna Therapeutics Corp. Transaction History

Millennium Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.5 - $0.78 $5,328 - $8,311	10,656 Added 18.51%	68,215 $44,000
Q4 2022 Feb 14, 2023	BUY	$0.4 - $0.68 $18,151 - $30,857	45,379 Added 372.57%	57,559 $27,000
Q3 2022 Nov 14, 2022	SELL	$0.83 - $1.78 $3,476 - $7,454	-4,188 Reduced 25.59%	12,180 $10,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.